IMMUNOPRECISE ANTIBODIES LTD (NASDAQ: $IPA ): CRYS
Post# of 49
(Total Views: 338)
Posted On: 05/20/2022 12:18:55 PM
IMMUNOPRECISE ANTIBODIES LTD (NASDAQ: $IPA ): CRYSTAL RESEARCH ASSOCIATES ISSUES RESEARCH REPORT
https://frontdesknews.com/2022/05/20/immunopr...ch-report/
Immunoprecise Antibodies Ltd (NASDAQ:IPA) is a full-service contract research organization (CRO) for therapeutic antibody discovery and development. The Company’s technology suite supports the biopharmaceutical industries in their pursuit to discover and develop novel, therapeutic antibodies against various disease targets.
Crystal Research Associates issued an research report on the company. The report states IPA is positioned as a leader in human therapeutic antibody discovery and development, disrupting the conventional multivendor drug discovery model by modernizing the antibody lead candidate selection and downstream development processes.
The Company is addressing one of the greatest challenges in generating new therapies, the lack of access to rigorous and innovative technologies (to serve a $30 billion market and growing).
IPA’s strategy is backed by expanding trends as pharmaceutical/biotechnology companies look to outsource research, improve efficiency, lower development costs, increase turnaround time, and gain access to integrated expertise.
https://frontdesknews.com/2022/05/20/immunopr...ch-report/
Immunoprecise Antibodies Ltd (NASDAQ:IPA) is a full-service contract research organization (CRO) for therapeutic antibody discovery and development. The Company’s technology suite supports the biopharmaceutical industries in their pursuit to discover and develop novel, therapeutic antibodies against various disease targets.
Crystal Research Associates issued an research report on the company. The report states IPA is positioned as a leader in human therapeutic antibody discovery and development, disrupting the conventional multivendor drug discovery model by modernizing the antibody lead candidate selection and downstream development processes.
The Company is addressing one of the greatest challenges in generating new therapies, the lack of access to rigorous and innovative technologies (to serve a $30 billion market and growing).
IPA’s strategy is backed by expanding trends as pharmaceutical/biotechnology companies look to outsource research, improve efficiency, lower development costs, increase turnaround time, and gain access to integrated expertise.
(0)
(0)